[go: up one dir, main page]

WO2005078117A3 - Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6) - Google Patents

Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6) Download PDF

Info

Publication number
WO2005078117A3
WO2005078117A3 PCT/EP2005/001136 EP2005001136W WO2005078117A3 WO 2005078117 A3 WO2005078117 A3 WO 2005078117A3 EP 2005001136 W EP2005001136 W EP 2005001136W WO 2005078117 A3 WO2005078117 A3 WO 2005078117A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
klk6
disorders
kallikrein
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/001136
Other languages
French (fr)
Other versions
WO2005078117A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP05707200A priority Critical patent/EP1718975A2/en
Publication of WO2005078117A2 publication Critical patent/WO2005078117A2/en
Publication of WO2005078117A3 publication Critical patent/WO2005078117A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458—Factor XII (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human KLK6 which is associated with the inflammation, muscle-skeleton diseases, hematological diseases, gastrointestinal and liver diseases, neurological disorders, urological disorders, cardiovascular disorders, cancer, metabolic diseases and dermatological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of inflammation, muscle-skeleton diseases, hematological diseases, gastrointestinal and liver diseases, neurological disorders, urological disorders, cardiovascular disorders, cancer, metabolic diseases and dermatological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK6 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/001136 2004-02-18 2005-02-04 Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6) Ceased WO2005078117A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05707200A EP1718975A2 (en) 2004-02-18 2005-02-04 Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003589 2004-02-18
EP04003589.1 2004-02-18

Publications (2)

Publication Number Publication Date
WO2005078117A2 WO2005078117A2 (en) 2005-08-25
WO2005078117A3 true WO2005078117A3 (en) 2006-04-20

Family

ID=34854560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001136 Ceased WO2005078117A2 (en) 2004-02-18 2005-02-04 Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)

Country Status (2)

Country Link
EP (1) EP1718975A2 (en)
WO (1) WO2005078117A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
US8530427B2 (en) * 2010-09-30 2013-09-10 Mayo Foundation For Medical Education And Research Methods for modulating resistance to apoptosis using KLK6
CN103889435A (en) * 2011-06-17 2014-06-25 约翰斯·霍普金斯大学 Methods for increasing insulin sensitivity and treating diabetes
FR2983868B1 (en) * 2011-12-07 2016-09-02 Oreal KLK6 AS A BIOMARKER FOR SCALP
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035232A2 (en) * 2000-10-27 2002-05-02 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
US20020182644A1 (en) * 2000-10-27 2002-12-05 Mount Sinai Hospital Methods for detecting Alzheimers disease
WO2003047572A1 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035232A2 (en) * 2000-10-27 2002-05-02 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
US20020182644A1 (en) * 2000-10-27 2002-12-05 Mount Sinai Hospital Methods for detecting Alzheimers disease
WO2003047572A1 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIAMANDIS ELEFTHERIOS P ET AL: "Human kallikrein 6 as a biomarker of Alzheimer's disease", CLINICAL BIOCHEMISTRY, vol. 33, no. 8, November 2000 (2000-11-01), pages 663 - 667, XP002339997, ISSN: 0009-9120 *
OGAWA K ET AL: "Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.", PSYCHIATRY AND CLINICAL NEUROSCIENCES. AUG 2000, vol. 54, no. 4, August 2000 (2000-08-01), pages 419 - 426, XP002339998, ISSN: 1323-1316 *
ZARGHOONI MARYAM ET AL: "Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients", CLINICAL BIOCHEMISTRY, vol. 35, no. 3, May 2002 (2002-05-01), pages 225 - 231, XP002339996, ISSN: 0009-9120 *

Also Published As

Publication number Publication date
EP1718975A2 (en) 2006-11-08
WO2005078117A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005075665A3 (en) Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2006008002A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2005022146A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005040401A3 (en) Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2005021781A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 9 (klk9)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005707200

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005707200

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005707200

Country of ref document: EP